The biotech sector is seen in China and internationally as a core area of national scientific and economic development.
[1][2] The CNCBD is an organization established on November 3, 1983, under the Ministry of Science and Technology with the approval of the State Council.
China's biotech industry registered sales totaling US$2.4 billion in 2000, compared with US$31 million in 1986.
The biopharmaceutical industry has begun to play a more important role in the national economy, drawing more attention from investors - both private and public.
Currently, blood products frequently used in clinical treatment include over 20 types, belonging to such 3 sub-catalogues as human serum albumin, immunoglobulin and coagulation factors.
The import and export volume of China's biopharmaceutical products was 377 million dollars in 2007, increased by 48% as compared with last year.
[1] Approved in 1982 and implemented for three Five-year Plans, the program includes three major issues: agriculture, new and high technologies and social development.